Document is current
Any future updates will be listed below
-
Authors
Mishra, Richa
Thunuguntla, Prasanth
Duraiyan, Dhanusha
Perkin, Alani
Bagwill, Katelyn https://orcid.org/0009-0008-7857-9442
Gonzales, Savannah https://orcid.org/0000-0001-8519-7671
Sizemore, Catheryn https://orcid.org/0009-0008-7431-2222
Brizuela, Vanessa
King, Jaiyana
Daly, Stephen https://orcid.org/0009-0007-8185-3142
Chang, Yoon Jae
Abebe, Mahdote
Rajana, Yash
Wichmann, Kelly
Enyan, Christ
Rangineni, Shruthi
Fiala, Mark
Fortier, Julie
Jayasinghe, Reyka https://orcid.org/0000-0003-2368-4890
Schroeder, Mark
Ding, Li https://orcid.org/0000-0003-1517-2975
Vij, Ravi
DiPersio, John
Silva-Fisher, Jessica https://orcid.org/0000-0002-8146-9331
-
Funding
Funding for this research was provided by:
WUSTL | Washington University School of Medicine in St. Louis (Faculty Diversity Scholar Awa)
Longer Life Foundation (No award number)
American Society of Hematology (No award number)
- License Information
-
More Information
Article History
Received: 17 December 2024
Revised: 21 August 2025
Accepted: 8 September 2025
First Online: 6 October 2025
Competing interests
: MS (Consulting for DSMB and endpoint adjudication work: Sorrento, Marker Therapeutics, GSK, Kura Oncology, and NovoNordisk; Research support: Incyte, Janssen, Takeda, Ichnos Biosciences, Fate Therapeutics, and Karyopharm), RV (Consulting: BMS, Sanofi, Janssen, Karyopharm, Pfizer, Regenron; Research: BMS, Sanofi, Takeda), and JD (Consulting: Rivervest, Bluebird Bio, Vertex, HcBiosciences, SPARC; Equity-ownership WUGEN and Magenta; Research support: Macrogenics, Bioline, Incyte).
: All methods were performed in accordance with relevant guidelines and regulations. This study was conducted under the supervision of the Washington University Human Rights Protections Office and in compliance with all relevant guidelines and regulations for clinical research. All participants in CoMMpass (NCT01454297) provided informed consent for that study. Only de-identified patient-level data was accessed for these analyses and, therefore, were determined to be exempt. NDMM patient bone marrow aspirates were obtained from the participants following informed consent and registration on our internal Multiple Myeloma Tissue Banking Protocol (protocol number 201102270). All animal experiment protocols in this study were reviewed and approved by the Institutional Animal Care and Use Committee of WashU (Protocol 24-0155).
